Literature DB >> 32329054

Association of C-reactive protein (CRP) rs1205 and rs2808630 variants and risk of cancer.

Hai-Yan Pan1, Yuan-Yuan Mi1, Kai Xu2, Ze Zhang2, Hao Wu2, Wei Zhang3, Wei Yuan4, Li Shi2, Li-Feng Zhang2, Li-Jie Zhu1, Li Zuo2.   

Abstract

The correlation between rs1205, rs2808630 variants of C-reactive protein (CRP) gene and susceptibility of cancer has been assessed previously, but with conflicting results. We adopted odds ratios (ORs) with 95% confidence intervals (CIs), in silico tools and enzyme-linked immunosorbent assay (ELISA) analysis to evaluate this association. Totally, 10,614 cancer subjects and 33,294 controls were involved in the pooled analysis. When all the studies were pooled, no significant correlation was indicated between the two variants and cancer risk. However, in stratification analysis by ethnicity, we found that CRP rs1205 C>T polymorphism was associated with an elevated risk of cancer in Asians (T-allele vs. C-allele, OR = 1.20, 95% CI = 1.06-1.36, pheterogeneity  = .226; TT vs. CC, OR = 1.48, 95% CI = 1.14-1.93, pheterogeneity  = .089). Similar findings were observed for rs2808630 variant. In silico tools showed that lung adenocarcinoma participants with high CRP expression may have shorter overall survival time than low expression group. ELISA analysis indicated that CRP expression in prostate adenocarcinoma subjects with TT + TC genotypes was statistically higher than in those with CC genotypes. CRP rs1205 C>T and rs2808630 T>C polymorphism may be associated with cancer risk, especially for Asians.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  CRP; cancer; genetic variation; in silico; polymorphism

Year:  2020        PMID: 32329054     DOI: 10.1002/jcp.29701

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  5 in total

1.  Pre-diagnostic C-reactive protein concentrations, CRP genetic variation and mortality among individuals with colorectal cancer in Western European populations.

Authors:  Katharina Nimptsch; Krasimira Aleksandrova; Veronika Fedirko; Mazda Jenab; Marc J Gunter; Peter D Siersema; Kana Wu; Verena Katzke; Rudolf Kaaks; Salvatore Panico; Domenico Palli; Anne M May; Sabina Sieri; Bas Bueno-de-Mesquita; Karina Standahl; Maria-Jose Sánchez; Aurora Perez-Cornago; Anja Olsen; Anne Tjønneland; Catalina Bonet Bonet; Christina C Dahm; María-Dolores Chirlaque; Valentina Fiano; Rosario Tumino; Aurelio Barricarte Gurrea; Marie-Christine Boutron-Ruault; Florence Menegaux; Gianluca Severi; Bethany van Guelpen; Young-Ae Lee; Tobias Pischon
Journal:  BMC Cancer       Date:  2022-06-24       Impact factor: 4.638

2.  Association between IL8RB C1208T mutation and risk of cancer: A pooled analysis based on 5299 cases and 6899 controls.

Authors:  He-Yun Sun; Zhi-Chao Min; Lei Gao; Zi-Yi Zhang; Ting-Le Pang; Ying-Jun Gao; Hong Pan; Jun Ou-Yang
Journal:  Medicine (Baltimore)       Date:  2022-02-25       Impact factor: 1.817

3.  Preoperative Serum Hypersensitive-c-Reactive-Protein (Hs-CRP) to Albumin Ratio Predicts Survival in Patients with Luminal B Subtype Breast Cancer.

Authors:  Xiujun Liu; Xiuchun Guo; Zhiqiang Zhang
Journal:  Onco Targets Ther       Date:  2021-07-09       Impact factor: 4.147

4.  HTRA1 rs11200638 variant and AMD risk from a comprehensive analysis about 15,316 subjects.

Authors:  Ying Liu; Huipeng Jin; Dong Wei; Wenxiu Li
Journal:  BMC Med Genet       Date:  2020-05-15       Impact factor: 2.103

5.  Effect of interleukin-8 receptor B (IL8RB) rs1126579 C>T variation on the risk to cancer.

Authors:  Lihong Zhu; Bowen Tang; Ze Zhang; Shuzhang Wei; Zhiwei Lv; Yujuan Zhang; Minlie Yang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.